Paradigm is building a new model for clinical trials, from the ground up. In doing so, we research, evaluate, and deploy the most efficient and functional technologies for each of the myriad of challenges to be solved.
Recently, we worked with OpenAI and evaluated GPT-4 as a tool to reduce the administrative burden of screening patients for clinical trials. While we had already shown internally that large language models perform better than machine learning approaches, we were surprised by how dramatically better GPT-4 performed than even a custom natural language model trained on medical use cases.
The breadth of our work, along with our need for simple, secure, and functional solutions that work together in a seamless solution for customers, makes Paradigm an exceptional partner for companies like OpenAI as they seek to apply new technologies in healthcare. We’re happy to share more details of the work and its real-world applications in a case study with OpenAI.
While there’s much more to be done, the potential to uniformly screen every patient faster, more accurately, and with dramatically lower cost than current models will lower a barrier to access and help create equitable access for any patient, anywhere.
About Paradigm
Paradigm is rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients, while enhancing trial efficiency and reducing the barriers to participation for healthcare providers. Incubated by ARCH Venture Partners and backed by leading healthcare and life sciences investors, Paradigm aims to break down barriers across the trial ecosystem through one seamless infrastructure implemented at healthcare provider organizations, bringing potentially life-saving therapies to patients faster.
